Open Access
| Numéro |
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 997 - 1000 | |
| Section | Anticorps nus et monospécifiques en cancérologie : quels autres progrès depuis 2009 ? | |
| DOI | https://doi.org/10.1051/medsci/2019197 | |
| Publié en ligne | 6 janvier 2020 | |
- Lacour B, Guyot-Goubin A, Guissou S, et al. Incidence of childhood cancer in France: nnational children cancer registries, 2000–2004. Eur J Cancer Prev 2010 ; 19: 173–181. [CrossRef] [PubMed] [Google Scholar]
- Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010 ; 363: 1324–1334. [Google Scholar]
- Ladenstein R, Poetschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 2018 ; 19: 1617–1629. [CrossRef] [PubMed] [Google Scholar]
- Lode HN, Valteau-Couanet D, Garaventa A, et al. Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients. J Clin Oncol 2015 ; 33: 10080. [Google Scholar]
- Mueller I, Ehlert K, Endres S, et al. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO. MAbs 2018; 10: 55–61. [CrossRef] [PubMed] [Google Scholar]
- Ladenstein R, Poetschger U, Valteau-Couanet D, et al. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: early results from the HR-NBL1/SIOPEN trial. J Clin Oncol 2019; 37 (abstract 10013). [Google Scholar]
- Ladenstein R, Poetschger U, Valteau-Couanet D, et al. Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within theHR-NBL1/SIOPEN trial improves outcome of high-risk neuroblastoma patients compare to historical controls. J Clin Oncol 2018; 36 (suppl 15): 10539. [Google Scholar]
- Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol 2017 ; 18: 946–957. [CrossRef] [PubMed] [Google Scholar]
- Furman WL, Shulkin BL, Federico SM, et al. Early response rates and Curie scores at end of induction: an update from a phase II study of an anti-GD2 monoclonal antibody with chemotherapy in newly diagnosed patients with high-risk neuroblastoma. J Clin Oncol 2017; 35 (abstract 10534). [Google Scholar]
- Terme M, Dorvillius M, Cochonneau D, et al. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PLoS One 2014 ; 9: e87210. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.